title: Exogenous calreticulin improves diabetic wound healing.
abstract: A serious consequence of diabetes mellitus is impaired wound healing, which largely resists treatment. We previously reported that topical application of calreticulin (CRT), an endoplasmic reticulum chaperone protein, markedly enhanced the rate and quality of wound healing in an experimental porcine model of cutaneous repair. Consistent with these in vivo effects, in vitro CRT induced the migration and proliferation of normal human cells critical to the wound healing process. These functions are particularly deficient in poor healing diabetic wounds. Using a genetically engineered diabetic mouse (db/db) in a full-thickness excisional wound healing model, we now show that topical application of CRT induces a statistically significant decrease in the time to complete wound closure compared with untreated wounds by 5.6 days (17.6 vs. 23.2). Quantitative analysis of the wounds shows that CRT increases the rate of reepithelialization at days 7 and 10 and increases the amount of granulation tissue at day 7 persisting to day 14. Furthermore, CRT treatment induces the regrowth of pigmented hair follicles observed on day 28. In vitro, fibroblasts isolated from diabetic compared with wild-type mouse skin and human fibroblasts cultured under hyperglycemic compared with normal glucose conditions proliferate and strongly migrate in response to CRT compared with untreated controls. The in vitro effects of CRT on these functions are consistent with CRT's potent effects on wound healing in the diabetic mouse. These studies implicate CRT as a potential powerful topical therapeutic agent for the treatment of diabetic and other chronic wounds.
authors.affiliation: Department of Medicine and Pathology, New York University School of Medicine, New York, New York 10016, USA.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Greives
authors.forename: Fares
authors.initials: F
authors.lastname: Samra
authors.forename: Savvas C
authors.initials: SC
authors.lastname: Pavlides
authors.forename: Keith M
authors.initials: KM
authors.lastname: Blechman
authors.forename: Sara-Megumi
authors.initials: SM
authors.lastname: Naylor
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Woodrell
authors.forename: Caprice
authors.initials: C
authors.lastname: Cadacio
authors.forename: Jamie P
authors.initials: JP
authors.lastname: Levine
authors.forename: Tara A
authors.initials: TA
authors.lastname: Bancroft
authors.forename: Marek
authors.initials: M
authors.lastname: Michalak
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Warren
authors.forename: Leslie I
authors.initials: LI
authors.lastname: Gold
mesh_terms: D000818:Animals; D037282:Calreticulin / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D004195:Disease Models, Animal; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism*; D006097:Granulation Tissue / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D016688:Mice, Inbred NOD; D014945:Wound Healing / Q000187:drug effects
chemical_list: D037282:Calreticulin